New Delhi, August 10, 2016: ClinTec International announces the appointment of Alastair MacDonald, Global Head of Clinical Operations, as the organisation continues to deliver on its ambitious global market-leading clinical research capabilities.
Alastair joins from AstraZeneca with almost 25 years’ experience in clinical development, most recently, as Global Medical Evidence and Observational Research Director at AstraZeneca. As a Global Delivery Director within AstraZeneca, Alastair made key contributions to the development pipeline and commercialisation, with a focus on oncology, and within other key strategic AstraZeneca areas including Cardiovascular, Metabolic and Respiratory Medicine. His significant oncology background includes recent contributions to the development and subsequent commercialisation of a number of key treatments across a broad range of cancer diseases.
Alastair was a Board Director of the Institute of Clinical Research (ICR), a premier organisation responsible for education, training and career development of clinical research professionals in the UK.In 2013 Alastair was awarded an Honorary Fellowship of the ICR. Alastair’s prior career includes the role of Regional Manager for SmithKline Beecham Pharmaceuticals (GlaxoSmithKline) ensuring clinical delivery for the UK local operating office and at Leo Pharmaceuticals, a Danish-based pharmaceutical company, where he specialised in the development of treatments for Dermatology and Pancreatic cancer.
Chief Operating Officer and Senior Executive Vice President of ClinTec International, Dr Robert Reekie commented: “As our company enters its 20th year of significant organic growth, we are delighted to have attracted Alastair to ClinTec International and look forward to bringing his industry leading operational talent and high calibre to bear in providing complementary leadership to our award winning clinical research project teams. In conjunction with our e-clinical technology platforms, this appointment further enhances our capability to meet and exceed the needs of our clients”.
Remarking on his appointment, Mr. MacDonald said: “As Global Head of Clinical Operations at ClinTec, I look forward to meeting exciting challenges in delivering clinical research excellence as we continue to grow our capabilities throughout our already extensive geographical reach. Our current suite of programs covers most therapeutic areas and, significantly, also includes complex projects in oncology and rare diseases that are intellectually and operationally challenging to deliver. It is the understanding that these studies have a real impact at the patient level, with diseases that in many cases are very debilitating, which brings the motivation to succeed”.
ClinTec International, a multi-award winning and privately owned Clinical Research Organisation (CRO), was formed nearly 20 years ago by its CEO and Chairman, Dr Rabinder Buttar. With capabilities in over 80 countries, ClinTec delivers innovative, customised clinical research solutions and talented personnel resourcing to the clinical development sector in a fast, flexible and focused way. ClinTec provides services to 7 of the world’s top 10 pharmaceutical companies, leading mid-market biopharmaceutical organisations, as well as small and medium-sized biotechnology companies. Through steady organic growth, ClinTec has evolved into a recognised global player within the clinical research outsourcing arena and is the most geographically diverse mid-market CRO in the world, with an operating platform on a par to its multi-billion dollar competitors. ClinTec has been recognised as the Best Mid-Sized Pharmaceutical CRO in the UK by Global Health and Pharma (GHP) Magazine’s 2016 International Life Sciences Awards and is a finalist in the Scale-up Business of the Year 2016 category for Minority Supplier Development UK’s (MSDUK) upcoming awards. ClinTec’s success lies in a twofold approach through providing flexible, customised solutions which meet its clients’ needs, whilst at the same time creating an excellent working environment that supports and nurtures its staff.
Corporate Comm India(CCI Newswire)
